Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix
Status: Completed
Location: See all (8) locations...
Intervention Type: Device, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Healthy Volunteers: f
View:
• Understand and sign an ethics committee-approved informed consent form;
• Willing and able to attend all scheduled study visits as required by the protocol;
• Planned cataract surgery (both eyes);
• Preoperative corneal astigmatism less that 1.00 diopter in each eye.
• Other protocol-defined inclusion criteria may apply.
Locations
United States
California
Wolstan & Goldberg Eye Associates
Torrance
Michigan
Grosinger, Spigelman & Grey Eye Surgeons, P.C.
Bloomfield Hills
Missouri
Moyes Eye Center
Kansas City
Ohio
Cincinnati Eye Institute
Cincinnati
South Carolina
Carolina Eyecare Physicians, LLC
Mt. Pleasant
Tennessee
Vision for Life
Nashville
Texas
Houston Eye Associates
Houston
Utah
The Eye Institute of Utah
Salt Lake City
Time Frame
Start Date: 2024-06-18
Completion Date: 2025-04-30
Participants
Target number of participants: 87
Treatments
Experimental: CPO Pro IOL
CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
Active_comparator: CPO IOL
CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
Related Therapeutic Areas
Sponsors
Leads: Alcon Research